Linker Information
General Information of This Linker
| Linker ID |
LIN0BDQFG
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Oxime-PEG3
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
| Structure |
|
|||||
| Formula |
C7H17NO4
|
|||||
| Isosmiles |
COCCOCCOCCON
|
|||||
| InChI |
InChI=1S/C7H17NO4/c1-9-2-3-10-4-5-11-6-7-12-8/h2-8H2,1H3
|
|||||
| InChIKey |
UPZRLQLRXOQKOM-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
179.216
|
Polar area
|
62.94
|
||
|
Complexity
|
179.115758
|
xlogp Value
|
-0.4437
|
|||
|
Heavy Count
|
12
|
Rot Bonds
|
9
|
|||
|
Hbond acc
|
5
|
Hbond Donor
|
1
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
ARX-517 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04662580 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
A phase 1/2, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517, with randomized comparison to investigator's choice of treatment, in subjects with metastatic castration-resistant prostate cancer who are resistant or refractory to prior standard therapies.
|
||||
References